Association between Tumor Regression Rate and Gene Expression Profile after Iodine 125 Plaque Radiotherapy for Uveal Melanoma

for the

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose Gene expression profile (GEP) testing segregates uveal melanoma (UM) into 2 main prognostic classes. It is unknown if a greater tumor regression response after iodine 125 (I125) brachytherapy correlates with class 2 GEP status. The purpose of this study was to determine whether there is a significant relationship between the rate of UM height regression and GEP classification testing after I125 plaque brachytherapy. Design Multicenter, retrospective cohort study. Participants Adult UM patients treated with I125 plaque brachytherapy who had concurrent tumor biopsy at the time of surgery with a GEP test result from January 1, 2010 through June 30, 2014. Methods Baseline clinical data and GEP class assignments were obtained. The ultrasonographic tumor height was recorded at baseline and at 3, 6, 9, and 12 months and at the most recent final follow-up visits. Subanalysis of paired cases based on pretreatment ultrasound height was performed. Statistical analysis was performed using Wilcoxon rank-sum tests, the Fisher exact test, and Kaplan-Meier analysis. Main Outcome Measures Percentage change in tumor height from baseline. Results A total of 353 patients were included in the study. Median follow-up was 2.1 years (range, 0.5–5.3 years). Gene expression profile status was class 1 in 247 tumors (70%) and class 2 in 106 tumors (30%). Increased patient age, larger tumor dimensions, and greater tumor thickness were associated with class 2 GEP status (P = 0.006, P < 0.001, and P < 0.001, respectively). The percentage reduction in tumor height from baseline was significantly greater in class 1 than class 2 tumors at 3 months (17.5% vs. 11.8%; P = 0.007) and 6 months (26.8% vs. 17.1%; P = 0.007), respectively, but there was no significant difference in reduction between class 1 and 2 tumors at 9 months (P = 0.26) and 12 months (P = 0.57) after treatment. Class 1A and 1B tumors showed similar reduction compared with class 2 tumors (P < 0.05). Conclusions Class 1 UM tumors tend to regress more rapidly than class 2 tumors in the first 6 months after plaque radiotherapy. Class 1A and 1B tumors regress at similar rates after plaque radiotherapy.

Original languageEnglish (US)
Pages (from-to)1532-1539
Number of pages8
JournalOphthalmology
Volume124
Issue number10
DOIs
StatePublished - Oct 1 2017

Fingerprint

Transcriptome
Iodine
Radiotherapy
Neoplasms
Brachytherapy
Uveal melanoma
Nonparametric Statistics
Kaplan-Meier Estimate
Cohort Studies

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Association between Tumor Regression Rate and Gene Expression Profile after Iodine 125 Plaque Radiotherapy for Uveal Melanoma. / for the.

In: Ophthalmology, Vol. 124, No. 10, 01.10.2017, p. 1532-1539.

Research output: Contribution to journalArticle

@article{9a1c18f7f480438cbb228fe7d5d5e206,
title = "Association between Tumor Regression Rate and Gene Expression Profile after Iodine 125 Plaque Radiotherapy for Uveal Melanoma",
abstract = "Purpose Gene expression profile (GEP) testing segregates uveal melanoma (UM) into 2 main prognostic classes. It is unknown if a greater tumor regression response after iodine 125 (I125) brachytherapy correlates with class 2 GEP status. The purpose of this study was to determine whether there is a significant relationship between the rate of UM height regression and GEP classification testing after I125 plaque brachytherapy. Design Multicenter, retrospective cohort study. Participants Adult UM patients treated with I125 plaque brachytherapy who had concurrent tumor biopsy at the time of surgery with a GEP test result from January 1, 2010 through June 30, 2014. Methods Baseline clinical data and GEP class assignments were obtained. The ultrasonographic tumor height was recorded at baseline and at 3, 6, 9, and 12 months and at the most recent final follow-up visits. Subanalysis of paired cases based on pretreatment ultrasound height was performed. Statistical analysis was performed using Wilcoxon rank-sum tests, the Fisher exact test, and Kaplan-Meier analysis. Main Outcome Measures Percentage change in tumor height from baseline. Results A total of 353 patients were included in the study. Median follow-up was 2.1 years (range, 0.5–5.3 years). Gene expression profile status was class 1 in 247 tumors (70{\%}) and class 2 in 106 tumors (30{\%}). Increased patient age, larger tumor dimensions, and greater tumor thickness were associated with class 2 GEP status (P = 0.006, P < 0.001, and P < 0.001, respectively). The percentage reduction in tumor height from baseline was significantly greater in class 1 than class 2 tumors at 3 months (17.5{\%} vs. 11.8{\%}; P = 0.007) and 6 months (26.8{\%} vs. 17.1{\%}; P = 0.007), respectively, but there was no significant difference in reduction between class 1 and 2 tumors at 9 months (P = 0.26) and 12 months (P = 0.57) after treatment. Class 1A and 1B tumors showed similar reduction compared with class 2 tumors (P < 0.05). Conclusions Class 1 UM tumors tend to regress more rapidly than class 2 tumors in the first 6 months after plaque radiotherapy. Class 1A and 1B tumors regress at similar rates after plaque radiotherapy.",
author = "{for the} and Prithvi Mruthyunjaya and Seider, {Michael I.} and Sandra Stinnett and Amy Schefler and Prithvi Mruthyunjaya and Michael Seider and Raufi, {Nikolas N.} and Duncan Berry and Sandra Stinnett and {William Harbour}, J. and Jesse Berry and Jonathan Kim and Alison Skalet and Audra Miller and Materin, {Miguel A.} and Tiffany Liu and Hakan Demirci and Ozkurt, {Zeynep G.} and Peter Hovland and Thomas Aaberg and Amy Schefler and Kim, {Ryan S.} and Anne Tann",
year = "2017",
month = "10",
day = "1",
doi = "10.1016/j.ophtha.2017.04.013",
language = "English (US)",
volume = "124",
pages = "1532--1539",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Association between Tumor Regression Rate and Gene Expression Profile after Iodine 125 Plaque Radiotherapy for Uveal Melanoma

AU - for the

AU - Mruthyunjaya, Prithvi

AU - Seider, Michael I.

AU - Stinnett, Sandra

AU - Schefler, Amy

AU - Mruthyunjaya, Prithvi

AU - Seider, Michael

AU - Raufi, Nikolas N.

AU - Berry, Duncan

AU - Stinnett, Sandra

AU - William Harbour, J.

AU - Berry, Jesse

AU - Kim, Jonathan

AU - Skalet, Alison

AU - Miller, Audra

AU - Materin, Miguel A.

AU - Liu, Tiffany

AU - Demirci, Hakan

AU - Ozkurt, Zeynep G.

AU - Hovland, Peter

AU - Aaberg, Thomas

AU - Schefler, Amy

AU - Kim, Ryan S.

AU - Tann, Anne

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Purpose Gene expression profile (GEP) testing segregates uveal melanoma (UM) into 2 main prognostic classes. It is unknown if a greater tumor regression response after iodine 125 (I125) brachytherapy correlates with class 2 GEP status. The purpose of this study was to determine whether there is a significant relationship between the rate of UM height regression and GEP classification testing after I125 plaque brachytherapy. Design Multicenter, retrospective cohort study. Participants Adult UM patients treated with I125 plaque brachytherapy who had concurrent tumor biopsy at the time of surgery with a GEP test result from January 1, 2010 through June 30, 2014. Methods Baseline clinical data and GEP class assignments were obtained. The ultrasonographic tumor height was recorded at baseline and at 3, 6, 9, and 12 months and at the most recent final follow-up visits. Subanalysis of paired cases based on pretreatment ultrasound height was performed. Statistical analysis was performed using Wilcoxon rank-sum tests, the Fisher exact test, and Kaplan-Meier analysis. Main Outcome Measures Percentage change in tumor height from baseline. Results A total of 353 patients were included in the study. Median follow-up was 2.1 years (range, 0.5–5.3 years). Gene expression profile status was class 1 in 247 tumors (70%) and class 2 in 106 tumors (30%). Increased patient age, larger tumor dimensions, and greater tumor thickness were associated with class 2 GEP status (P = 0.006, P < 0.001, and P < 0.001, respectively). The percentage reduction in tumor height from baseline was significantly greater in class 1 than class 2 tumors at 3 months (17.5% vs. 11.8%; P = 0.007) and 6 months (26.8% vs. 17.1%; P = 0.007), respectively, but there was no significant difference in reduction between class 1 and 2 tumors at 9 months (P = 0.26) and 12 months (P = 0.57) after treatment. Class 1A and 1B tumors showed similar reduction compared with class 2 tumors (P < 0.05). Conclusions Class 1 UM tumors tend to regress more rapidly than class 2 tumors in the first 6 months after plaque radiotherapy. Class 1A and 1B tumors regress at similar rates after plaque radiotherapy.

AB - Purpose Gene expression profile (GEP) testing segregates uveal melanoma (UM) into 2 main prognostic classes. It is unknown if a greater tumor regression response after iodine 125 (I125) brachytherapy correlates with class 2 GEP status. The purpose of this study was to determine whether there is a significant relationship between the rate of UM height regression and GEP classification testing after I125 plaque brachytherapy. Design Multicenter, retrospective cohort study. Participants Adult UM patients treated with I125 plaque brachytherapy who had concurrent tumor biopsy at the time of surgery with a GEP test result from January 1, 2010 through June 30, 2014. Methods Baseline clinical data and GEP class assignments were obtained. The ultrasonographic tumor height was recorded at baseline and at 3, 6, 9, and 12 months and at the most recent final follow-up visits. Subanalysis of paired cases based on pretreatment ultrasound height was performed. Statistical analysis was performed using Wilcoxon rank-sum tests, the Fisher exact test, and Kaplan-Meier analysis. Main Outcome Measures Percentage change in tumor height from baseline. Results A total of 353 patients were included in the study. Median follow-up was 2.1 years (range, 0.5–5.3 years). Gene expression profile status was class 1 in 247 tumors (70%) and class 2 in 106 tumors (30%). Increased patient age, larger tumor dimensions, and greater tumor thickness were associated with class 2 GEP status (P = 0.006, P < 0.001, and P < 0.001, respectively). The percentage reduction in tumor height from baseline was significantly greater in class 1 than class 2 tumors at 3 months (17.5% vs. 11.8%; P = 0.007) and 6 months (26.8% vs. 17.1%; P = 0.007), respectively, but there was no significant difference in reduction between class 1 and 2 tumors at 9 months (P = 0.26) and 12 months (P = 0.57) after treatment. Class 1A and 1B tumors showed similar reduction compared with class 2 tumors (P < 0.05). Conclusions Class 1 UM tumors tend to regress more rapidly than class 2 tumors in the first 6 months after plaque radiotherapy. Class 1A and 1B tumors regress at similar rates after plaque radiotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85019554412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019554412&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2017.04.013

DO - 10.1016/j.ophtha.2017.04.013

M3 - Article

C2 - 28549517

AN - SCOPUS:85019554412

VL - 124

SP - 1532

EP - 1539

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 10

ER -